Histological type Tissue collection Sample size Success rate Maximum passage Drug screening panel Reference
Adenocarcinoma Metastatic lesion Salvage prostatectomy 5 1 14% (7/49) More than 4 N/A [22]
Adenocarcinoma Adenocarcinoma Adenocarcinoma Neuroendocrine Neuroendocrine Adenocarcinoma CTC Metastatic lesion CTC PDX Prostatectomy & metastatic lesion PDX PDX Metastatic lesion Primary tumor 1 N/A 6 11 3 1 4 1 15% 16% (4/25) N/A N/A 7 days 7 days More than 10 5 N/A 74 anticancer compounds 17 anticancer compounds Anti-B7-H3 ADC Anti-B7-H3 ADC EZH2 inhibitor 129 anticancer compounds EZH2 inhibitor DRD2 antagonist [73] [74] [75] [49] [44]